| Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder S Krempien, A Inamdar, M Shenouda, K Johnson, SA Maass-Robinsin, ... NEUROPSYCHOPHARMACOLOGY 48, 195-196, 2023 | | 2023 |
| Early Clinical Development of a Deuterated N, N-Dimethyltryptamine (DMT) Analog for the Treatment of Mental Health Conditions A Inamdar, K van der Heijden, P Nathan, A Reichelt, A Hegle, M Otto, ... NEUROPSYCHOPHARMACOLOGY 48, 310-311, 2023 | | 2023 |
| Translational Studies of AZD4041, a First In-Class Selective Orexin 1 Receptor Antagonist for the Treatment of Opioid Use Disorder P Nathan, P Kenny, T Kamenecka, G Meno-Tetang, N Sane, S Soleman, ... NEUROPSYCHOPHARMACOLOGY 48, 451-451, 2023 | | 2023 |
| Safety, pharmacokinetics and pharmacodynamics of n, n-dimethyltryptamine administered as intravenous infusion in healthy smokers K Van Der Heijden, SM Boloni, R Zuiker, M Otto, AP Hegle, A Reichelt, ... Neuroscience Applied 2, 103731, 2023 | | 2023 |
| A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with … PJ Nathan, SB Millais, A Godwood, O Dewit, DM Cross, J Liptrot, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 8 (1 …, 2022 | 4 | 2022 |
| Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a … C Bakker, T Tasker, J Liptrot, EP Hart, ES Klaassen, RJ Doll, GA Brown, ... Alzheimer's Research & Therapy 13, 1-19, 2021 | 15 | 2021 |
| From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease AJH Brown, SJ Bradley, FH Marshall, GA Brown, KA Bennett, J Brown, ... Cell 184 (24), 5886-5901. e22, 2021 | 54 | 2021 |
| Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial C Bakker, S Prins, J Liptrot, EP Hart, ES Klaassen, GA Brown, A Brown, ... British Journal of Clinical Pharmacology 87 (11), 4439-4449, 2021 | 1 | 2021 |
| Acetylcholine prioritises direct synaptic inputs from entorhinal cortex to CA1 by differential modulation of feedforward inhibitory circuits J Palacios-Filardo, M Udakis, GA Brown, BG Tehan, MS Congreve, ... Nature communications 12 (1), 5475, 2021 | 32 | 2021 |
| Spatial Covariance of Cholinergic Muscarinic M1/M4 Receptors in Parkinson's Disease SJ Colloby, PJ Nathan, G Bakker, RA Lawson, AJ Yarnall, DJ Burn, ... Movement Disorders 36 (8), 1879-1888, 2021 | 8 | 2021 |
| First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the … C Bakker, T Tasker, J Liptrot, EP Hart, ES Klaassen, S Prins, ... British Journal of Clinical Pharmacology 87 (7), 2945-2955, 2021 | 13 | 2021 |
| Cognitive Go/No-Go decision-making criteria in Alzheimer’s disease drug development AM Wessels, CJ Edgar, PJ Nathan, ER Siemers, P Maruff, J Harrison Drug Discovery Today 26 (5), 1330-1336, 2021 | 3 | 2021 |
| Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption PJ Nathan, G Bakker Psychopharmacology 238 (5), 1255-1263, 2021 | 6 | 2021 |
| Safety, cand exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study. C Bakker, T Tasker, J Liptrot, EP Hart, ES Klaassen, RJ Doll, GA Brown, ... Alzheimer's Research & Therapy 13 (1), NA-NA, 2021 | | 2021 |
| Author Correction: Acetylcholine prioritises direct synaptic inputs from entorhinal cortex to CA1 by differential modulation of feedforward inhibitory circuits J Palacios-Filardo, M Udakis, GA Brown, BG Tehan, MS Congreve, ... Nature Communications 12, 2021 | 1 | 2021 |
| Convergent and discriminant validity of default mode network and limbic network perfusion in amnestic mild cognitive impairment patients G Quattrini, M Marizzoni, FB Pizzini, IB Galazzo, M Aiello, M Didic, ... Journal of Alzheimer's Disease 82 (4), 1797-1808, 2021 | 7 | 2021 |
| Brain perfusion in Alzheimer’s disease networks and association with pathophysiological features in mild cognitive impairment patients. G Quattrini, M Marizzoni, FB Pizzini, IB Galazzo, M Didic, A Soricelli, ... AAIC Neuroscience Next, 2020 | | 2020 |
| Brain perfusion changes in Alzheimer's disease networks and their association with pathophysiological features in amnestic mild cognitive impairment patients. G Quattrini, M Marizzoni, FB Pizzini, IB Galazzo, M Didic, A Soricelli, ... EUROPEAN JOURNAL OF NEUROLOGY 27, 375-375, 2020 | | 2020 |
| Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies SJ Colloby, PJ Nathan, IG McKeith, G Bakker, JT O’Brien, JP Taylor Brain Communications 2 (2), fcaa098, 2020 | 10 | 2020 |
| Basal Forebrain Volumes Predict Circuit Specific Functional Sensitivity to Muscarinic M1 Receptor Modulation on Cognitive Function in Healthy Controls and Patients with … P Nathan, G Bakker, A Godwood, C Vingerhoets, M Caan, O Bloemen, ... NEUROPSYCHOPHARMACOLOGY 44 (SUPPL 1), 173-173, 2019 | | 2019 |
Con StoughAdjunct Professor, Swinburne University of TechnologyVerified email at swin.edu.au
